The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease.

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...

Federal regulators have rejected Merck & Co.'s new combination cholesterol drug, which includes a generic version of the mega-blockbuster Lipitor — at least for now.It's unclear how long the ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck & Co. Inc.’s MRK new supplemental Biologics License Application (sBLA) seeking approval to update ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...